SCHEDULE 13G/A: Lagoda Investment Management Discloses 10.56% Passive Stake in VolitionRX Ltd
Beneficial Ownership Statement
Lagoda Investment Management, L.P. has filed an amended Schedule 13G, revealing a significant passive beneficial ownership of 10.56% in VolitionRX Ltd.
Summary
- Lagoda Investment Management, L.P. (the "Reporting Person") has filed an Amendment No. 2 to Schedule 13G regarding its beneficial ownership in VolitionRX Ltd.
- As of March 31, 2025, the Reporting Person beneficially owns 10,194,000 shares of Common Stock of VolitionRX Ltd.
- This ownership represents 10.56% of the Issuer's outstanding Common Stock.
- The calculation is based on 96,543,744 shares outstanding as of March 20, 2025, as disclosed in VolitionRX Ltd.'s Annual Report on Form 10-K for the fiscal year ended December 31, 2024.
- Lagoda Investment Management, L.P. serves as the investment manager to certain managed accounts and holds sole voting and sole dispositive power over these shares.
- The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 7
Explanation: The disclosure of a significant passive stake by an institutional investor is generally viewed positively as it indicates confidence in the company, although it does not provide operational or financial performance details.
Positives
- The disclosure of a significant 10.56% stake by an institutional investor like Lagoda Investment Management, L.P. can be viewed as a vote of confidence in VolitionRX Ltd.'s long-term prospects.
- The passive nature of the investment, as stated in the filing, suggests that the investor is not seeking to influence control, which can provide stability.
Future Outlook
This document does not contain forward-looking statements or guidance from the issuer or the reporting person regarding future performance or strategic direction.
Industry Context
This Schedule 13G filing indicates a significant passive investment by an institutional asset manager in a publicly traded company. Such filings are routine disclosures required by the SEC when an investor's beneficial ownership crosses a 5% threshold, providing transparency into major shareholder positions. For companies like VolitionRX Ltd., having institutional investors can signal market confidence and potentially increase liquidity.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional stake may instill greater confidence among existing shareholders and potentially attract new investors, as it signals a professional assessment of the company's value.
- Management: While the investment is passive, management may view this as validation of their strategy and operations, potentially influencing future investor relations efforts.
Key Dates
| Date | Description |
|---|---|
| 2024-12-31 | Fiscal year end for VolitionRX Ltd.'s Annual Report on Form 10-K. |
| 2025-03-20 | Date as of which VolitionRX Ltd. reported 96,543,744 shares outstanding in its Form 10-K. |
| 2025-03-31 | Date of event which requires the filing of this Schedule 13G; also the filing date of VolitionRX Ltd.'s Annual Report on Form 10-K. |
| 2025-04-07 | Signature date of the Schedule 13G filing by Lagoda Investment Management, L.P. |
Keywords
VolitionRX Ltd, Lagoda Investment Management, Schedule 13G, Beneficial Ownership, Institutional Investor, SEC Filing, Common Stock, Passive Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.